HOOF Torsten

Torsten Hoof joined Genomic Health in 2017 as Senior Vice President, International, directing GHIs international expansion to ensure that the innovative suite of products and services to aid treatment decisions will provide benefit to many more patients and their health care providers around the world.
Torsten joined GHI from Baxalta where he built the company’s oncology presence in Europe executing the European-wide launches of treatments for ALL and ovarian cancer. Prior to that as General Manager Europe Torsten established Endocyte’s European presence designed to bring an innovative Personalized Medicines solution to patients with ovarian cancer.
During his 10 years tenure as an executive at Bristol-Myers Squibb he led the global haemato-oncology franchise and as EMEA General Manager and Vice President for HIV and Primary Care built strong teams, directed multiple launches and drove the growth of multi billion $ portfolios.
In the earlier stages of his career with Roche Torsten led the Tamiflu launch as Global Business Leader and established Roche’s German leadership position in Virology in the mid 90’s.
Torsten also served as an Independent Director at HRA Pharma until its acquisition by Goldman-Sachs/Astorg in 2016. Torsten holds a master’s degree with distinction in Biochemistry from the University of Hannover and his work on drug resistance in cancer was awarded with a PhD by the same institution. Torsten is an Alumnus of the Boehringer Ingelheim Fonds.